Baird lowered the firm’s price target on DexCom (DXCM) to $90 from $112 and keeps an Outperform rating on the shares. The firm updated its model following the mixed Seagrove survey. Baird maintains expanding NIT T2 reimbursement remains key for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: